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Abstract 
Introduction and objectives. To study the prognostic value of serum lactate in patients under temporary preoperative 
mechanical circulatory support who underwent urgent heart transplant. 
Methods. We conducted a subanalysis of a Spanish multicenter registry recording data on patients under temporary 
mechanical circulatory support listed for highly urgent heart transplant from 2010 to 2015. Participants selected for 
the present study were those who received a transplant and who had known preoperative serum lactate levels. The 
main study outcome was 1-year survival after transplant. 
Results. A total of 177 heart transplant recipients were studied; preoperatively, 90 were supported on venoarterial 
extracorporeal membrane oxygenation, 51 on temporary left ventricular assist devices, and 36 on temporary 
biventricular assist devices. Preoperative hyperlactatemia (≥ 2 mmol/L) was present in 44 (25%) patients. On 
multivariable analysis, pretransplant serum lactate was identified as an independent predictor of 1-year posttransplant 
survival (adjusted HR per 0.1 mmol/L, 1.02; 95%CI, 1.01-1.03; P = .007). One-year posttransplant survival was 
53.1% (95%CI, 45.3-60.9) in patients with preoperative hyperlactatemia and 75.6% (95%CI, 71.8-79.4) in those 
without preoperative hyperlactatemia (adjusted HR, 1.94; 95%CI, 1.04-3.63; P = .039). Preoperative hyperlactatemia 
correlated with adverse outcomes in patients supported with extracorporeal membrane oxygenation, but not in 
patients supported on ventricular assist devices. 
Conclusions. Preoperative serum lactate is a strong independent predictor of worse outcomes in patients undergoing 
urgent heart transplant on short-term mechanical circulatory support. 
Resumen 
Introducción y objetivos. Analizar el impacto del lactato sérico en receptores de trasplante cardiaco urgente en 
asistencia circulatoria mecánica de corta duración preoperatoria. 
Métodos. Se realizó un subanálisis de un registro multicéntrico español basado en pacientes incluidos en «urgencia 
grado 0» para trasplante cardiaco con asistencia circulatoria mecánica preoperatoria de corta duración entre 2010 y 
2015. Se seleccionó a los receptores de trasplante con cifras preoperatorias de lactato conocidas. El desenlace 
principal fue la supervivencia 1 año tras el trasplante. 
Resultados. Se estudió a 177 receptores de trasplante cardiaco urgente, de los que 90 necesitaron asistencia 
preoperatoria con oxigenador extracorpóreo de membrana venoarterial, 51 con asistencia ventricular izquierda y 36 
con asistencia biventricular. De ellos, 44 (25%) presentaban hiperlactatemia antes del trasplante (≥ 2 mmol/l). En el 
análisis multivariable, la cifra de lactato sérico resultó predictora independiente de mortalidad tras el trasplante (cada 
0,1 mmol/l, HR ajustada = 1,02; IC95%, 1,01-1,03; p = 0,007). La supervivencia estimada al año del trasplante 
cardiaco fue del 53,1% (IC95%, 45,3-60,9) en los pacientes con hiperlactactemia preoperatoria y el 75,6% (IC95%, 
71,8-79,4) en los pacientes sin hiperlactatemia (HR ajustada = 1,94; IC95%, 1,04-3,63; p = 0,039). El impacto 
pronóstico de la hiperlactatemia fue significativo en los pacientes asistidos con oxigenador extracorpóreo de 
membrana venoarterial, pero no en aquellos con dispositivos de asistencia ventricular. 
Conclusiones. Los valores preoperatorios de ácido láctico son un potente factor pronóstico independiente en 
receptores de trasplante cardiaco urgente. 
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In recent years, an increasing number of heart transplant (HT) recipients have received the organ on 
an urgent basis. Most of these patients require the use of preoperative support with mechanical circulatory 
support (MCS) devices.
1
 Under these circumstances, hemodynamic status is a strong indicator of the risk 
of mortality and clinical complications after HT, with poorer prognosis seen in patients in cardiogenic 




Lactic acidosis is a serious and relatively common metabolic abnormality in patients with low cardiac 
output caused by a tissue oxygen supply-demand imbalance secondary to tissue hypoperfusion.
3
 Serum 
lactate levels have been investigated as a marker of adverse prognosis in a wide variety of patients with 
acute heart disease,
4
 such as acute myocardial infarction, decompensated heart failure, or cardiogenic 
shock, as well as in patients undergoing cardiopulmonary bypass.
5
 In some HT recipients, lactic acidosis 
has been described during the immediate postoperative period,
6
 although the causes and clinical impact of 
this phenomenon are uncertain. 
 
The aim of the present study was to analyze a potential association between preoperative serum lactate 
and outcome in patients on temporary MCS listed for highly urgent HT. The working hypothesis was that 
serum lactate may be higher in patients with worse pretransplant hemodynamic status and thus, 
theoretically at higher risk of posttransplant mortality, such that lactate may be used as a prognostic 
predictor in these individuals. To fulfill this objective, the study analyzed information from a Spanish 
multicenter HT registry. 
METHODS 
Study Description 
The ASIS-TC (Use of Short-term Mechanical Circulatory Support Devices as a Bridge to Urgent 
Heart Transplant in Spain) study is a retrospective multicenter registry which collected data on all patients 
over age 18 years listed for a highly urgent first HT who were receiving support with MCS devices from 
2010 to 2015 in Spain. The study did not include patients with a previous HT or listed for multiorgan 
transplant. The registry included all 16 Spanish hospitals with an adult HT program. 
 
The ASIS-TC study recorded information on patients listed with the National Transplant Organization 
for HT as “grade 0 urgency” (assisted with venoarterial extracorporeal membrane oxygenation [ECMO] 
or short-term ventricular assist devices) or “grade 1 urgency” (assisted with intra-aortic balloon pump 
counterpulsation). For the purpose of the study, short-term ventricular assist devices were considered to 
include the Impella Recover (percutaneous insertion, continuous flow), Levitronix Centrimag (surgical 
insertion, continuous flow), Abiomed BVS5000 (surgical insertion, pulsing flow), and similar devices. 




The registry information was obtained by an individualized, case-by-case review of all medical 
records for included patients. Individuals were identified for the study by approved queries of the 
National Transplant Organization database, with cooperation by local and autonomous community 
transplant coordination offices for participating hospitals. 
 
For each patient, more than 500 variables were collected on clinical characteristics during circulatory 
assist and at the time of HT, as well as on the type of device implanted, complications associated with 
circulatory assist, waiting list times, and posttransplant complications. Several additional variables related 
to donor characteristics, HT surgical procedure, and long-term posttransplant survival were obtained by 
targeted queries of the National Heart Transplant Registry. 
  
The study protocol was approved by the Clinical Research Ethics Committee of Galicia and was 
ratified by the ethics committees at each participating site. 
 
We describe the results of a subanalysis of the ASIS–TC registry database focused on the prognostic 
value of serum lactate in patients receiving an urgent HT. The individuals selected for these analyses were 
patients from the “grade 0 urgency” cohort who underwent HT with registry database information on 
pretransplant serum lactate. Patients were not included in the analyses if they died before HT or had been 
excluded from the urgent waiting list. 
Statistical Analysis 
A descriptive and comparative analysis was performed of study patients’ baseline (at HT) clinical 
characteristics according to the presence or absence of preoperative hyperlactatemia, defined as serum 
lactate ≥ 2 mmol/L at the last determination during the pretransplant waiting period. This is the most 




Quantitative variables are expressed as mean ± standard deviation, and the proportion of affected 
participants was used for qualitative variables. Study group distributions for qualitative variables were 
compared by the chi-square test or by the Student t test for continuous quantitative variables. 
 
The primary endpoint was 1-year survival after HT. The Kaplan-Meier method was used to construct 
survival curves over the entire period, and survival probability between study groups was compared by 
the log-rank test. 
 
To identify 1-year posttransplant mortality predictors, a Cox multivariate regression was run 
backwards stepwise with “P out” < .05. The first step of this analysis included clinical variables for the 
donor and recipient with a proven univariate association with posttransplant risk of death with P < .20 
(recipient age, diabetes mellitus, mechanical ventilation, renal replacement therapy, ECMO-type MCS, 
serum creatinine, hemoglobin, vasoactive-inotropic score, serum lactate, ischemia time). The multivariate 
model obtained by the backwards stepwise analysis was subsequently used to estimate the hazard ratio 
(HR) for 1-year posttransplant mortality in patients with preoperative hyperlactatemia (≥ 2 mmol/L) 
compared with patients without hyperlactatemia (< 2 mmol/L). A P value < .05 was considered 
significant for all hypothesis contrasts. The statistical analysis was performed using SPSS 20. 
RESULTS 
Patients 
From January 2010 to December 2015, 291 patients were listed with the National Transplant 
Organization for HT with a “grade 0 urgency” priority and on a temporary MCS device at 16 Spanish 
sites; 230 of these patients received HT. The ASIS–TC registry database contained information on 
preoperative serum lactate levels for 177 (77%) of these urgent HT recipients, who comprised our study 
population. 
 
At the time of HT, 90 patients were on venoarterial ECMO, 64 with Levitronix Centrimag (26 
biventricular and 38 left ventricular), 13 with Abiomed BVS5000 (9 biventricular and 4 left ventricular), 
9 with Impella Recover (left ventricular), and 1 with biventricular Abiomed AB5000. 
 
Serum lactate levels before urgent HT in the study population are shown in Figure 1. The mean ± 
standard deviation was 1.8 ± 1.7 mmol/L; 44 recipients (25%) of had pretransplant hyperlactatemia, 





Figure 1. Distribution of pretransplant serum lactate levels in the study 
population. 
Clinical Characteristics of Patients With and Without Hyperlactatemia 
Table 1 compares the baseline clinical characteristics of all patients included in the subanalysis, based 
on the presence or absence of preoperative hyperlactatemia. Baseline clinical characteristics of the 177 
urgent HT recipients in the cohort analyzed were similar to those of the 230 urgent HT recipients in the 
overall ASIS–TC cohort. 
  
Table 1. Comparison of Baseline Clinical Characteristics for Study Patients According to the Presence or Absence of Pretransplant 
Hyperlactatemia 
Variables Lactate < 2 mmol/L (n = 133) Lactate ≥ 2 mmol/L (n = 44) P 
 
Recipient characteristics 
 Age, y 50.9 ± 12.2 49.8 ± 13.6 .604 
 Women, % 19 34 .035 
 MCS type, %   .147 
  Venoarterial ECMO 50 55  
  Left ventricular assist 32 18  
  Biventricular assist 18 27  
 MCS duration, d 14.5 ± 12.6 12.5 ± 17.3 .747 
 Time on urgent waiting list, d 8.2 ± 9.2 7.1± 6.3 .458 
 Ischemic heart disease, % 51 48 .696 
 Diabetes mellitus, % 24 20 .623 
 History of heart surgery, % 20 21 .896 
 Cardiopulmonary arrest, % 17 18 .801 
 Active infection requiring IV therapy, % 13 18 .373 
 INTERMACS profile 1 or 2, % 74 80 .493 
 Intra-aortic balloon pump counterpulsation, % 23 27 .524 
 Renal replacement therapy, % 9 11 .648 
 Invasive mechanical ventilation, % 61 73 .048 
 Vasoactive-inotropic score 16 ± 43 48 ± 74 .015 
 Creatinine, mg/dL 1.03 ± 0.6 1.29 ± 0.8 .022 
 Hemoglobin, g/dL 9.2 ± 1.1 9.6 ± 2.0 .216 
 Bilirubin, mg/dL 1.8 ± 2.5 1.6 ± 1.7 .641 
 GOT, IU/L 97 ± 250 102 ± 100 .906 
 Albumin, g/dL 2.9 ± 0.7 2.6 ± 1 .247 
 INR 1.3 ± 0.2 1.4 ± 0.4 .165 
 pH 7.43 ± 0.1 7.42 ± 0.1 .502 
 Lactate, mmol/L 1.1 ± 0.4 3.9 ± 3.4 < .001 
 Left ventricular ejection fraction, % 23 ± 12 22 ± 10 .638 
 Cardiac index, mL/min/m2 2.3 ± 0.6 2.3 ± 0.7 .989 
 Mean pulmonary pressure, mmHg 29 ± 13 26 ± 10 .322 
Donor characteristics 
 Age, y 42.7 ± 11.5 43.4 ± 13.4 .747 
 Women, % 27 27 .979 
 Ischemia time, min 215 ± 62 222 ± 47 .449 
    
 
ECMO, extracorporeal membrane oxygenation; GOT, glutamic oxaloacetic transaminase; INTERMACS, Interagency Registry for 
Mechanically Assisted Circulatory Support; MCS, mechanical circulatory support. 
Unless otherwise indicated, the date are expressed as mean ± standard deviation. 
There was a higher proportion of women among patients with hyperlactatemia, and the latter were 
more likely to be on invasive mechanical ventilation and to have higher serum creatinine and higher 
vasoactive-inotropic score before HT. Mean pretransplant serum lactate was 1.1 ± 0.4 mmol/L in patients 
without hyperlactatemia and 3.9 ± 3.4 mmol/L in patients with hyperlactatemia. 
  
Posttransplant Survival 
A total of 52 (29.4%) patients died during the first year after HT; 48 of these deaths occurred during 
the immediate postoperative hospitalization. 
 
The Cox univariate analysis showed a statistically significant association between preoperative serum 
lactate and 1-year posttransplant risk of death (per 0.1 mmol/L, crude HR = 1.01; 95% confidence 
interval [95%CI], 1.00-1.02; P = .040). Figure 2 shows the Kaplan-Meier survival curves during this 
period, with stratification of the study population by preoperative serum lactate tertiles. The log-rank test 
showed a statistically significant linear trend for 1-year posttransplant mortality in the higher preoperative 




Figure 2. One-year posttransplant survival curves, stratified by preoperative 
serum lactate tertiles. Tertile 1: preoperative serum lactate < 1 mmol/L; tertile 2: 
1.00-1.69 mmol/L; tertile 3: ≥ 1.7 mmol/L. 
In the Cox multivariate analysis, preoperative serum lactate was an independent predictor of higher 1-
year posttransplant risk of death (per 0.1 mmol/L, adjusted HR = 1.02; 95%CI, 1.01-1.03; P = .007). 
Other independent predictors of mortality were recipient age, ischemia time, vasoactive-inotropic score, 
and pretransplant venoarterial ECMO, as shown in Table 2. 
Table 2. Independent Predictors of 1-year Posttransplant Mortality: Cox 
Multivariate Analysis 
 
HR (95%CI) P 
   
Age, per 10 y 1.52 (1.15-2.03) .004 
Vasoactive-inotropic score, per 10 units 1.05 (1.01-1.10) .021 
Ischemia time, per h 1.80 (1.26-2.57) .001 
Venoarterial ECMO 2.35 (1.27-4.35) .007 
Serum lactate, per 0.1 mmol/L 1.02 (1.01-1.03) .007 
   
 
95%CI, 95% confidence interval; ECMO, extracorporeal membrane oxygenation; 
HR, hazard ratio. 
According to the Kaplan-Meier estimate, the probability of 1-year posttransplant survival was 53.1% 
(95%CI, 45.3-60.9) for patients with preoperative hyperlactatemia (≥ 2 mmol/L) and 75.6% (95%CI, 
71.8-79.4) for patients without hyperlactatemia (P = .011). The adjusted HR for 1-year posttransplant 
mortality in patients with preoperative hyperlactatemia (≥ 2 mmol/L) compared with patients without 
hyperlactatemia was 1.94 (95%CI, 1.04-3.63; P = .039). 
Causes of Death 
Table 3 lists the causes of posttransplant death based on the presence or absence of preoperative 
hyperlactatemia (≥ 2 mmol/L). In patients with hyperlactatemia, bacterial infections (n = 7 [35%]), 
primary graft failure (n = 5 [25%]), and postoperative multiorgan failure (n = 4 [20%]) were the most 
common causes of mortality, accounting for 80% of all deaths. Patients without hyperlactatemia showed 
more variety in the causes of mortality, with the most frequent being primary graft failure (n = 10 [31%]). 
Table 3. Causes of 1-Year Posttransplant Death in Patients With and Without Preoperative 
Hyperlactatemia 
 
Lactate < 2 mmol/L  
(n = 32/133), no. 
Lactate ≥ 2 mmol/L  
(n = 20/44), no. 
   
Primary graft failure 10 5 
Postoperative multiorgan failure 4 4 
Surgical hemorrhage 2 1 
Technical complication 1 0 
Bacterial infection 3 7 
Cytomegalovirus infection 1 0 
Aspergillus infection 1 0 
Ischemic stroke 2 1 
Hemorrhagic stroke 3 0 
Postanoxic encephalopathy 2 0 
Hyperacute rejection 1 0 
Acute rejection 1 1 
Neoplasm 0 1 
Sudden cardiac death 1 0 
   
Types of Mechanical Circulatory Support 
Figure 3 contains the 1-year posttransplant Kaplan-Meier survival curves for patients with and without 




Figure 3. One-year posttransplant survival curves according to the presence or 
absence of hyperlactatemia (serum lactate ≥ 2 mmol/L) prior to surgery. A, 
patients with venoarterial extracorporeal membrane oxygenation. B, patients 
with temporary ventricular assist devices. 
In the subgroup of patients supported with venoarterial ECMO, preoperative hyperlactatemia was 
associated with a statistically significant increase in 1-year posttransplant mortality (P = .024); however, 
no significant differences were observed in posttransplant mortality between patients with and without 
preoperative hyperlactatemia in the subgroup of recipients on short-term ventricular assist devices (P = 
.301).  
DISCUSSION 
We present a subanalysis of the ASIS–TC multicenter registry database, which collects clinical 
information on all patients listed for urgent HT on temporary MCS devices at 16 Spanish sites between 
2010 and 2015. The main result of this study is the evidence that preoperative serum lactate is of 
significant prognostic impact in this population. In fact, after multivariate adjustment, the risk of early 
mortality after urgent HT was almost 2-fold for recipients with preoperative hyperlactatemia (≥ 2 
mmol/L) compared with the rest of the study population. 
 
Because serum lactate can be measured quickly and simply, its clinical value has been investigated 
widely in the critical medicine setting.
8
 The earliest observations were made by Weil and Afifi,
3
 and 
several later studies have reported that lactic acidosis is a diagnostic component and a marker of adverse 
prognosis in patients with acute heart disease and circulatory shock
4
 as well as in patients with severe 
sepsis,
9
 multiple injuries, and critical neurologic disease. 
 
In the context of cardiogenic shock, lactic acidosis is mainly the result of tissue hypoperfusion, which 
leads to a net oxygen supply-demand imbalance in target organs. However, other pathophysiologic 
mechanisms contribute to this phenomenon. Additionally, high circulating catecholamines are present in 
shock situations—either as a physiologic response to low cardiac output or as a consequence of the 
treatment itself—which favors an increase in sarcolemmal Na/K ATPase activity, thus leading to 
increased glycogenolysis and aerobic glycolysis, raising serum lactate.
10
 Patients with decompensation of 
pre-existing advanced heart failure seem to be particularly vulnerable in this regard, due to a tendency to 
move rapidly from aerobic to anaerobic metabolism.
11
 Last, patients with cardiogenic shock, particularly 
if they require invasive ventilatory or circulatory assist, are prone to septic complications that can cause 




Preoperative hyperlactatemia (≥ 2 mmol/L) was a common laboratory finding in this population, as it 
affected 1 of every 4 recipients of urgent HT. Due to its design, the study only included lactate levels 
nearest to the time of HT; in fact, hyperlactatemia would probably have been more common if the study 
had included levels obtained during the acute phase of cardiogenic shock prior to MCS use. Furthermore, 
moderately elevated lactate among patients with hyperlactatemia (mean, 3.9 mmol/L) indicates that there 
may be some selection bias in the sample analyzed, ie, the health care team may have excluded some 
patients with refractory cardiogenic shock and severe metabolic acidosis from the HT waiting list, 
believing that it might be ineffectual. 
 
Apart from these considerations, the study shows a direct association between serum lactate before 
urgent HT and postoperative mortality. The practical importance of this result is obvious, particularly 
because this clinical scenario accounts for almost half the HT procedures currently performed in Spain
1
 
and because this high-risk context is precisely where clinical tools are most needed to stratify postsurgery 
prognosis and to identify situations where a successful outcome is unlikely. As expected, most 
posttransplant HT deaths in this cohort occurred during the immediate postoperative period, and the most 
common causes of mortality were primary graft failure, postoperative multiorgan failure, and sepsis. 
 
The statistical association observed is even more interesting due to its biological plausibility and its 
independence of other adverse prognostic factors in the context of urgent HT that might correlate with 
lactate levels, such as vasoactive-inotropic score,
12
 a recently validated formula to standardize the 
vasoactive support doses received by a critically-ill patient. Moreover, the association between 
preoperative lactate levels and posttransplant mortality HT shows a dose-response relationship, such that 
patients with borderline values considered normal-to-high, eg, patients in the second tertile of the sample 
distribution (1.00-1.69 mmol/L), were at higher risk than patients with strictly normal values (< 1 
mmol/L). The ability of preoperative lactate to predict prognosis in urgent HT recipients was even 
stronger in individuals with a higher risk profile, such as those supported by venoarterial ECMO.7, 13 
  
The elevated postoperative mortality observed with pretransplant hyperlactatemia (nearly 50% at 1 
year of follow-up) indicates the need to reconsider the therapeutic approach in these patients. Persistent 
lactic acidosis despite adequate MCS should lead the health care team to question the suitability of listing 
the patient for urgent HT at that time or accepting an organ if the patient is already listed. In patients in an 
early phase of cardiogenic shock, it might be sufficient to defer HT listing several days to allow 
hemodynamic status to normalize and metabolic abnormalities and target organ function to be corrected, 
thus permitting HT to be undertaken with greater expectations of success. In patients with a longer 
course, the development of progressive lactic acidosis in the absence of other underlying causes (eg, 
sepsis) might indicate poor clinical progress and multiorgan failure which, if persistent, would 
contraindicate HT due to the unlikelihood of a successful outcome. 
Limitations 
This study has several limitations. The first is related to the observational and retrospective nature of 
the registry, which may have led to the selection, information, or confusion biases inherent to this type of 
study. As stated in the Methods section, 53 recipients of urgent HT were excluded from this subanalysis 
due to a lack of information on their preoperative lactate levels; however, the clinical characteristics and 
posttransplant mortality of patients included in the subanalysis were generally consistent with those of the 
registry as a whole. 
 
In view of the retrospective nature of the registry, it was not possible to define a priori the same 
specific time point for serum lactate determinations in all patients; moreover, because this was a 
multicenter study without a single core laboratory, the test results may be subject to local variations. 
There was also no information on postoperative serum lactate trends after HT. Last, serum lactate ≥ 2 
mmol/L was arbitrarily selected as a cutoff to define hyperlactatemia due to widespread acceptance in the 
medical literature. However, the use of alternative cutoff points was not explored in this analysis to avoid 
problems of multiple comparisons, which might have led to different conclusions from those obtained. 
CONCLUSIONS 
This study supports the independent prognostic value of preoperative serum lactate levels of patients 
on temporary MCS devices who undergo urgent HT. In recipients with preoperative hyperlactatemia (≥ 2 
mmol/L), mortality is high during the early postoperative stage after urgent HT—nearly 50% at 1 year of 
follow-up—, suggesting the need to reconsider the therapeutic approach taken in this complex clinical 
scenario. 
 
According to the results obtained, persistent serum lactate elevation in a candidate for urgent HT in 
MCS should be considered a warning sign for the transplant team. Hyperlactatemia is a sensitive but 
nonspecific marker of an adverse clinical course. This may be because MCS is insufficient in time or 
intensity, because irreversible multiorgan failure is already established, or because there are other 
intercurrent processes, such as undetected sepsis. For some patients, the correct decision in this scenario 
may be to wait for greater hemodynamic stability, for recovery of target organ function, or for treatment 
of an intercurrent process before listing them for urgent HT. In other patients, the most appropriate option 
may to limit therapeutic efforts due to poor prognosis and give the organ to another recipient more likely 
to survive posttransplant. 
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